Ignite Creation Date:
2024-05-06 @ 8:22 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06354413
Status:
COMPLETED
Last Update Posted:
2024-04-09
First Post:
2024-04-02
Brief Title:
Outcomes of Concomitant Bypass Surgery in Septal Myectomy
Sponsor:
Chinese Academy of Medical Sciences Fuwai Hospital
Organization:
Chinese Academy of Medical Sciences Fuwai Hospital
Study Overview
Official Title:
Establishing a Database of Patients Undergoing Surgery for Hypertrophic Cardiomyopathy Concomitant Bypass Surgery
Status:
COMPLETED
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To investigate clinical characteristics and survival outcomes of patients with obstructive hypertrophic cardiomyopathy who underwent concomitant coronary artery bypass grafting during septal myectomy
Detailed Description:
Surgical septal myectomy SM is an effective approach for treating patients with drug-refractory obstructive hypertrophic cardiomyopathy HCMHowever numerous patients with HCM exhibit concurrent ischemic heart disease including atherosclerotic coronary artery disease CAD and myocardial bridging MB Although patients with HCM have been known to possess diminished coronary flow reserveadditional CAD can worsen myocardial ischemia contributing to an unfavorable prognosisMB although infrequent may affect diastolic heart perfusion leading to angina and even sudden deathCurrent guidelines recommend revascularization for ischemic heart disease caused by CAD and MBHowever the impact of concomitant coronary revascularization during HCM management remains unclear In this study we analyzed the clinical characteristics and surgical scenarios of patients who underwent concomitant coronary artery bypass grafting CABG during ventricular SM and investigated their prognosis
Patient clinical and survival data from 2009-2020 were retrospectively reviewed The median follow-up period was 51 years All-cause mortality was the primary endpoint
Patient clinical and survival data from 2009-2020 were retrospectively reviewed The median follow-up period was 51 years All-cause mortality was the primary endpoint
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None